Association of free PSA percent, total PSA, age, and gland volume in the detection of prostate cancer

Prostate

Volumn 39, Issue 3, 1999, Pages 153-158

  Mettlin, Curtis ^a   Chesley, Arthur E ^b   Murphy, Gerald P ^c   Bartsch, Georg ^d   Toi, Ants ^e   Bahnson, Robert ^f   Church, Paul ^g  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Prost Cancer Detection Clinic Inc   (Canada)

^c NORTHWEST HOSPITAL   (United States)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^g HARVARD UNIVERSITY   (United States)

Author keywords

Free prostate specific antigen percent; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; ECHOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 0033135408     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990515)39:3<153::AID-PROS2>3.0.CO;2-V     Document Type: Article

References (16)

1. 1-antichymotypsin before diagnosis of prostate cancer. Lancet 1994;344:1594-1598.
2. Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK, Thiel R. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urol 1995;46:187-194.
3. Van Cangh PJ, De Nayer P, Sauvage P, Tombal B, Elsen M, Lorge F, Opsomer R, Wese FX. Free to total prostate-specific antigen (PSA) ration is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate [Suppl] 1996;7:30-34.
4. Chen YT, Luderer AA, Thiel RP, Carlson G, Cuny CL, Soriano TF. Using proportions of free to total prostate-specific antigen, age, and total prostate specific-antigen to predict the probability of prostate cancer. Urology 1996;47:518-524.
5. Partin AW, Catalona WJ, Southwick PC, Suboang EN, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of PSA, prostate volume, and age. Urology [Suppl] 1996;48:55-61.
6. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997;277:1452-1455.
7. Bangma CH, Rietbergen JBW, Kranse R, Blijenberg BG, Petterson K, Schroder FH. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol 1997;157:2191-2196.
8. Morote J, Raventos CX, Lorente JA, Lopez-Pacios MA, Encabo G, de Torres I, Andreu J. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng/ml. J Urol 1997; 158:502-504.
9. Wolff JM, Boeckmann W, Effert PJ, Habib FK, Jakse G. Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA. Anticancer Res 1997;17:2993-2994.
10. Catalona WJ, Beiser JA, Smith DS. Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J Urol 1997;158:2162-2167.
11. Wechsel PHW, Petri E, Bichler KH, Schreiber M. Free PSA in the detection of prostatic carcinoma. Anticancer Res 1997;17:3015-3018.
12. Lodding P, Aus G, Bergdahl S, Frosing R, Lilja H, Pihl CG, Hugosson J. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml prostate specific antigen. J Urol 1998;159:899-903.
13. Murphy GP, Barren RJ, Erickson SJ, Bowes VA, Wolfert RL, Bartsch G, Klocker H, Pointner J, Reissigl A, McLeod DG, Douglas T, Morgan T, Kenny GM, Ragde H, Boynton AL, Holmes EH. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen. Cancer 1996;78:809-818.
14. SPSS for Windows 8.0. Chicago: SPSS, Inc.; 1997.
15. Haese A, Graefen M, Noldus J, Hammerer P, Huland E, Huland H. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. J Urol 1997;158:2188-2192.
16. Ornstein DK, Smith DS, Humphrey PA, Catalona WJ. The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer. J Urol 1998;159:1234-1237.